{"success":true,"data":{"pressRelease":{"id":"158161","rtpr_id":"nGNX6kxBSP-20261001","ticker":"NUWE","exchange":"NASDAQ","all_tickers":["NUWE"],"title":"Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences","author":"Globe Newswire","published_at":"2026-10-01T12:30:00.457Z","article_body":"MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE),\na medical technology company committed to delivering solutions for patients\nwith cardiorenal conditions, today announced its participation in four leading\nmedical conferences in October spanning pediatrics, critical care, and heart\nfailure. Across the events, Nuwellis will engage directly with clinicians on\nthe challenge of fluid overload and the role of its Aquadex SmartFlow(®)\nsystem in providing precise, controlled fluid removal for patients who require\nindividualized fluid management.\n\n“Pediatrics, critical care, and heart failure are the three key growth\nmarkets for Nuwellis, and fluid overload is a common and complex challenge\nacross each of these patient populations,” said Mike McCormick, Nuwellis\nPresident and Chief Executive Officer. “By engaging clinicians and\nspecialists at leading meetings across all three markets, we are advancing our\ncommercial strategy while increasing awareness of Aquadex and its ability to\nprovide precise, adjustable fluid removal when conventional approaches may be\ninsufficient. These conferences give us an important opportunity to deepen\nrelationships with the specialists caring for patients who can benefit from\nmore individualized fluid management.”\n\nPediatric Paracorporeal and Extracorporeal Therapies Summit (PPETS)\nOctober 6-8 | Houston | Texas Children's Hospital\nPPETS brings together pediatric specialists focused on extracorporeal\ntherapies and critically ill children.\nFor more information, visit the event’s website\n(https://www.globenewswire.com/Tracker?data=zrFJGvi2SClLyvrnbcipSbpy5w-BPmILTBkxeWTy11ali9kaHpLxrGccVNCZTX4oSBNoVEVo3IB_mA3eD9hF960FW3u40C_8l6uzs-IS_KGNed4ybFqxkwLCAxW6zgzJK8AYhUPYdu0mPb7xp3oIjt6nu4xmh81N5aJ5rtPzAsSlkiuYU-KjBHNU_AidaseVhMnnq43I86cFgLrO1Zw_7z9HOXV5hDrUY7Rhi3cAtG8=).\n\n2026 Society of Thoracic Surgeons (STS) Perioperative & Critical Care\nConference\nOctober 9-10 | Baltimore | Hyatt Regency Baltimore Inner Harbor \nThe STS Perioperative & Critical Care Conference convenes cardiovascular and\nthoracic critical care teams managing complex patients, including those facing\nheart failure, acute kidney injury, and volume management challenges.\nFor more information, visit the event’s website\n(https://www.globenewswire.com/Tracker?data=zrFJGvi2SClLyvrnbcipSRWsXjiT_jPc0O74VNVDOzWsXXdNobfgFVJgZor1q74-Wa5D-TW5LIsyZSCSUNg3sUev02f6VAq66bAP7zQsF0Y2ZOtYKE9V-PFqUGkT5T08dLJAlrMmtSo5jv0pPsjOhNMaByAM5mKpdpUJ5gqNVrI=).\n\nHeart Failure Society of America (HFSA) Annual Scientific Meeting 2026\nOctober 9-12 | Phoenix | Phoenix Convention Center\nNuwellis’ Booth at the HFSA Devices Meeting on October 9: 204\nThe HFSA Annual Scientific Meeting brings together the multidisciplinary heart\nfailure community across advanced, hospitalized, and chronic heart failure\ncare.\nFor more information, visit the event’s website\n(https://www.globenewswire.com/Tracker?data=zrFJGvi2SClLyvrnbcipSQjEaB7b-1P7dHlU0n38ea9HEHVheFMapZzoYQFeJoP1Y4jwAU5w-Y2CbAM6-djxw0T6G3nj5x9X7Fh3Ox4PtkyWaSAsRHKgG3FP6zTs6UKn).\n\nAmerican Society of Nephrology’s (ASN) Kidney Week 2026\nOctober 21-25 | Denver | Colorado Convention Center\nNuwellis’ Booth: 391\nKidney Week 2026 is ASN's annual meeting bringing together over 12,000 kidney\nprofessionals to latest treatments and advancements in and related to the\nfield, including across critical care nephrology, pediatric care, and heart\nfailure. \nFor more information, visit the event’s website\n(https://www.globenewswire.com/Tracker?data=zrFJGvi2SClLyvrnbcipSdeojDHtIkSKxt48H0SjEbDM81SlE_F27J4pdxDtFhmI8VyfF5_tIN8qU4CQKfIWFcSXWCFiVWy7_zgjd2VGifdODpSHd2ZMJCCTfgRcGGq_).\n\nAbout Aquadex\nThe Aquadex SmartFlow System is currently indicated for the continuous\nultrafiltration therapy for temporary (up to 8 hours) or extended (longer than\n8 hours in patients who require hospitalization) use in adult and pediatric\npatients weighing 20 kilograms or more whose fluid overload is unresponsive to\nmedical management, including diuretics. All treatments must be administered\nby a healthcare provider, within an outpatient or inpatient clinical setting,\nunder physician prescription, both of whom having received training in\nextracorporeal therapies.\n\nAbout Nuwellis\nNuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to\ndelivering solutions for patients with cardiorenal conditions. The Company\ndevelops solutions designed to support patient care through monitoring,\ntherapy, and data-informed clinical decision-making across acute and chronic\ncare settings. Nuwellis' strategy includes expanding its portfolio through\ninternally developed technologies and strategic commercial partnerships that\nbroaden its presence across acute and chronic critical care. For more\ninformation, visit www.nuwellis.com.\n\nForward-Looking Statements\nCertain statements in this release may be considered forward-looking\nstatements within the meaning of the Private Securities Litigation Reform Act\nof 1995, including without limitation, statements regarding the new market\nopportunities and anticipated growth in 2026 and beyond. Forward-looking\nstatements are predictions, projections and other statements about future\nevents that are based on current expectations and assumptions and, as a\nresult, are subject to risks and uncertainties. Many factors could cause\nactual future events to differ materially from the forward-looking statements\nin this release, including, without limitation, those risks associated with\nour ability to execute on our commercialization strategy, the possibility that\nwe may be unable to raise sufficient funds necessary for our anticipated\noperations, our post-market clinical data collection activities, benefits of\nour products to patients, our expectations with respect to product development\nand commercialization efforts, our ability to increase market and physician\nacceptance of our products, potentially competitive product offerings,\nintellectual property protection, our ability to integrate acquired\nbusinesses, our expectations regarding anticipated synergies with and benefits\nfrom acquired businesses, and other risks and uncertainties described in our\nfilings with the SEC. Forward-looking statements speak only as of the date\nwhen made. Nuwellis does not assume any obligation to publicly update or\nrevise any forward-looking statements, whether due to new information, future\nevents or otherwise.\n\nFor further information, please contact:\n\nInvestor Relations: \nCORE IR\nir@nuwellis.com\n\nMedia Contact: \nCORE PR\nmedia@nuwellis.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/92c460b4-3e5c-4a6f-a33c-636a1520d076)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6kxBSP-20261001","title":"Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences","author":"Globe Newswire","ticker":"NUWE","created":"2026-10-01T12:30:00.457Z","tickers":["NUWE"],"exchange":"NASDAQ","article_body":"MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE),\na medical technology company committed to delivering solutions for patients\nwith cardiorenal conditions, today announced its participation in four leading\nmedical conferences in October spanning pediatrics, critical care, and heart\nfailure. Across the events, Nuwellis will engage directly with clinicians on\nthe challenge of fluid overload and the role of its Aquadex SmartFlow(®)\nsystem in providing precise, controlled fluid removal for patients who require\nindividualized fluid management.\n\n“Pediatrics, critical care, and heart failure are the three key growth\nmarkets for Nuwellis, and fluid overload is a common and complex challenge\nacross each of these patient populations,” said Mike McCormick, Nuwellis\nPresident and Chief Executive Officer. “By engaging clinicians and\nspecialists at leading meetings across all three markets, we are advancing our\ncommercial strategy while increasing awareness of Aquadex and its ability to\nprovide precise, adjustable fluid removal when conventional approaches may be\ninsufficient. These conferences give us an important opportunity to deepen\nrelationships with the specialists caring for patients who can benefit from\nmore individualized fluid management.”\n\nPediatric Paracorporeal and Extracorporeal Therapies Summit (PPETS)\nOctober 6-8 | Houston | Texas Children's Hospital\nPPETS brings together pediatric specialists focused on extracorporeal\ntherapies and critically ill children.\nFor more information, visit the event’s website\n(https://www.globenewswire.com/Tracker?data=zrFJGvi2SClLyvrnbcipSbpy5w-BPmILTBkxeWTy11ali9kaHpLxrGccVNCZTX4oSBNoVEVo3IB_mA3eD9hF960FW3u40C_8l6uzs-IS_KGNed4ybFqxkwLCAxW6zgzJK8AYhUPYdu0mPb7xp3oIjt6nu4xmh81N5aJ5rtPzAsSlkiuYU-KjBHNU_AidaseVhMnnq43I86cFgLrO1Zw_7z9HOXV5hDrUY7Rhi3cAtG8=).\n\n2026 Society of Thoracic Surgeons (STS) Perioperative & Critical Care\nConference\nOctober 9-10 | Baltimore | Hyatt Regency Baltimore Inner Harbor \nThe STS Perioperative & Critical Care Conference convenes cardiovascular and\nthoracic critical care teams managing complex patients, including those facing\nheart failure, acute kidney injury, and volume management challenges.\nFor more information, visit the event’s website\n(https://www.globenewswire.com/Tracker?data=zrFJGvi2SClLyvrnbcipSRWsXjiT_jPc0O74VNVDOzWsXXdNobfgFVJgZor1q74-Wa5D-TW5LIsyZSCSUNg3sUev02f6VAq66bAP7zQsF0Y2ZOtYKE9V-PFqUGkT5T08dLJAlrMmtSo5jv0pPsjOhNMaByAM5mKpdpUJ5gqNVrI=).\n\nHeart Failure Society of America (HFSA) Annual Scientific Meeting 2026\nOctober 9-12 | Phoenix | Phoenix Convention Center\nNuwellis’ Booth at the HFSA Devices Meeting on October 9: 204\nThe HFSA Annual Scientific Meeting brings together the multidisciplinary heart\nfailure community across advanced, hospitalized, and chronic heart failure\ncare.\nFor more information, visit the event’s website\n(https://www.globenewswire.com/Tracker?data=zrFJGvi2SClLyvrnbcipSQjEaB7b-1P7dHlU0n38ea9HEHVheFMapZzoYQFeJoP1Y4jwAU5w-Y2CbAM6-djxw0T6G3nj5x9X7Fh3Ox4PtkyWaSAsRHKgG3FP6zTs6UKn).\n\nAmerican Society of Nephrology’s (ASN) Kidney Week 2026\nOctober 21-25 | Denver | Colorado Convention Center\nNuwellis’ Booth: 391\nKidney Week 2026 is ASN's annual meeting bringing together over 12,000 kidney\nprofessionals to latest treatments and advancements in and related to the\nfield, including across critical care nephrology, pediatric care, and heart\nfailure. \nFor more information, visit the event’s website\n(https://www.globenewswire.com/Tracker?data=zrFJGvi2SClLyvrnbcipSdeojDHtIkSKxt48H0SjEbDM81SlE_F27J4pdxDtFhmI8VyfF5_tIN8qU4CQKfIWFcSXWCFiVWy7_zgjd2VGifdODpSHd2ZMJCCTfgRcGGq_).\n\nAbout Aquadex\nThe Aquadex SmartFlow System is currently indicated for the continuous\nultrafiltration therapy for temporary (up to 8 hours) or extended (longer than\n8 hours in patients who require hospitalization) use in adult and pediatric\npatients weighing 20 kilograms or more whose fluid overload is unresponsive to\nmedical management, including diuretics. All treatments must be administered\nby a healthcare provider, within an outpatient or inpatient clinical setting,\nunder physician prescription, both of whom having received training in\nextracorporeal therapies.\n\nAbout Nuwellis\nNuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to\ndelivering solutions for patients with cardiorenal conditions. The Company\ndevelops solutions designed to support patient care through monitoring,\ntherapy, and data-informed clinical decision-making across acute and chronic\ncare settings. Nuwellis' strategy includes expanding its portfolio through\ninternally developed technologies and strategic commercial partnerships that\nbroaden its presence across acute and chronic critical care. For more\ninformation, visit www.nuwellis.com.\n\nForward-Looking Statements\nCertain statements in this release may be considered forward-looking\nstatements within the meaning of the Private Securities Litigation Reform Act\nof 1995, including without limitation, statements regarding the new market\nopportunities and anticipated growth in 2026 and beyond. Forward-looking\nstatements are predictions, projections and other statements about future\nevents that are based on current expectations and assumptions and, as a\nresult, are subject to risks and uncertainties. Many factors could cause\nactual future events to differ materially from the forward-looking statements\nin this release, including, without limitation, those risks associated with\nour ability to execute on our commercialization strategy, the possibility that\nwe may be unable to raise sufficient funds necessary for our anticipated\noperations, our post-market clinical data collection activities, benefits of\nour products to patients, our expectations with respect to product development\nand commercialization efforts, our ability to increase market and physician\nacceptance of our products, potentially competitive product offerings,\nintellectual property protection, our ability to integrate acquired\nbusinesses, our expectations regarding anticipated synergies with and benefits\nfrom acquired businesses, and other risks and uncertainties described in our\nfilings with the SEC. Forward-looking statements speak only as of the date\nwhen made. Nuwellis does not assume any obligation to publicly update or\nrevise any forward-looking statements, whether due to new information, future\nevents or otherwise.\n\nFor further information, please contact:\n\nInvestor Relations: \nCORE IR\nir@nuwellis.com\n\nMedia Contact: \nCORE PR\nmedia@nuwellis.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/92c460b4-3e5c-4a6f-a33c-636a1520d076)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-01T12:30:00.523845674Z","server_sent_at_ms":1790857800523},"received_at":"2026-10-01T12:30:00.574Z","source_url":null},"analysis":{"id":"146800","press_release_id":"158161","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Nuwellis announced it will participate in four medical conferences in October spanning pediatrics, critical care, and heart failure.\n\nThe company will showcase the Aquadex SmartFlow system for precise, controlled fluid removal, including booths at the HFSA Devices Meeting and ASN Kidney Week 2026.\n\nCEO Mike McCormick framed the three segments as the company's key growth markets, with conference engagement part of the commercial awareness strategy.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference-calendar update -- no new data or financials; suppress."},"keyFigures":{"customDimensions":{"conferences_attending":4,"asn_kidney_week_attendees":"over 12,000"}},"quotedText":"Pediatrics, critical care, and heart failure are the three key growth markets for Nuwellis, and fluid overload is a common and complex challenge across each of these patient populations","namedEntities":{"people":[{"name":"Mike McCormick","role":"President and CEO"}],"products":["Aquadex SmartFlow System"],"companies":[{"name":"Nuwellis, Inc.","ticker":"NUWE","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of conference participation to promote the Aquadex SmartFlow system. No new clinical data, revenue figures, or strategic change disclosed."},"tickerRelevance":{"others":[],"primary":"NUWE"},"globalImportance":10,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"routine-conference-participation","issuerAuthored":true}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Nuwellis announced it will participate in four medical conferences in October spanning pediatrics, critical care, and heart failure.\n\nThe company will showcase the Aquadex SmartFlow system for precise, controlled fluid removal, including booths at the HFSA Devices Meeting and ASN Kidney Week 2026.\n\nCEO Mike McCormick framed the three segments as the company's key growth markets, with conference engagement part of the commercial awareness strategy.","key_figures":{"customDimensions":{"conferences_attending":4,"asn_kidney_week_attendees":"over 12,000"}},"named_entities":{"people":[{"name":"Mike McCormick","role":"President and CEO"}],"products":["Aquadex SmartFlow System"],"companies":[{"name":"Nuwellis, Inc.","ticker":"NUWE","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-01T12:30:11.695Z","global_importance":10,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap","eventGravity":"routine-conference-participation","issuerAuthored":true}},"durationMs":4790,"modelName":"glm-5.3-flashx"}}